These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37464124)

  • 21. Role of Biologics in Asthma.
    McGregor MC; Krings JG; Nair P; Castro M
    Am J Respir Crit Care Med; 2019 Feb; 199(4):433-445. PubMed ID: 30525902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guiding principles for use of newer biologics and bronchial thermoplasty for patients with severe asthma.
    Blaiss MS; Castro M; Chipps BE; Zitt M; Panettieri RA; Foggs MB
    Ann Allergy Asthma Immunol; 2017 Dec; 119(6):533-540. PubMed ID: 29103801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils).
    Petsky HL; Cates CJ; Lasserson TJ; Li AM; Turner C; Kynaston JA; Chang AB
    Thorax; 2012 Mar; 67(3):199-208. PubMed ID: 20937641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers and asthma management: analysis and potential applications.
    Richards LB; Neerincx AH; van Bragt JJMH; Sterk PJ; Bel EHD; Maitland-van der Zee AH
    Curr Opin Allergy Clin Immunol; 2018 Apr; 18(2):96-108. PubMed ID: 29389730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Different endotypes and phenotypes drive the heterogeneity in severe asthma.
    McDowell PJ; Heaney LG
    Allergy; 2020 Feb; 75(2):302-310. PubMed ID: 31267562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovering Pediatric Asthma Phenotypes on the Basis of Response to Controller Medication Using Machine Learning.
    Ross MK; Yoon J; van der Schaar A; van der Schaar M
    Ann Am Thorac Soc; 2018 Jan; 15(1):49-58. PubMed ID: 29048949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
    Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study.
    McDowell PJ; Diver S; Yang F; Borg C; Busby J; Brown V; Shrimanker R; Cox C; Brightling CE; Chaudhuri R; Pavord ID; Heaney LG;
    Lancet Respir Med; 2021 Oct; 9(10):1174-1184. PubMed ID: 33971168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?
    De Ferrari L; Chiappori A; Bagnasco D; Riccio AM; Passalacqua G; Canonica GW
    Expert Rev Respir Med; 2016; 10(1):29-38. PubMed ID: 26566089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [THE OVERLAPPING ELIGIBILITY FOR BIOLOGICS IN PATIENTS WITH SEVERE ASTHMA AND PHENOTYPES].
    Ito A; Miyoshi S; Toyota H; Suzuki Y; Uehara Y; Hattori S; Takeshita Y; Sakasegawa H; Kuramochi M; Kobayashi K; Sugimoto N; Nagase H
    Arerugi; 2022; 71(3):210-220. PubMed ID: 35569943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Childhood asthma in the new omics era: challenges and perspectives.
    Golebski K; Kabesch M; Melén E; Potočnik U; van Drunen CM; Reinarts S; Maitland-van der Zee AH; Vijverberg SJH;
    Curr Opin Allergy Clin Immunol; 2020 Apr; 20(2):155-161. PubMed ID: 31985545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions.
    Oppenheimer J; Hoyte FCL; Phipatanakul W; Silver J; Howarth P; Lugogo NL
    Ann Allergy Asthma Immunol; 2022 Aug; 129(2):169-180. PubMed ID: 35272048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis.
    Di Bona D; Crimi C; D'Uggento AM; Benfante A; Caiaffa MF; Calabrese C; Campisi R; Carpagnano GE; Ciotta D; D'Amato M; Pelaia C; Pelaia G; Pellegrino S; Scichilone N; Scioscia G; Ribecco N; Spadaro G; Valenti G; Vatrella A; Crimi N; Macchia L
    Clin Exp Allergy; 2022 Feb; 52(2):312-323. PubMed ID: 34608696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biologic and New Therapies in Asthma.
    Tabatabaian F; Ledford DK; Casale TB
    Immunol Allergy Clin North Am; 2017 May; 37(2):329-343. PubMed ID: 28366480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
    Emma R; Morjaria JB; Fuochi V; Polosa R; Caruso M
    Ther Adv Respir Dis; 2018; 12():1753466618808490. PubMed ID: 30354852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treating severe asthma: Targeting the IL-5 pathway.
    Principe S; Porsbjerg C; Bolm Ditlev S; Kjaersgaard Klein D; Golebski K; Dyhre-Petersen N; van Dijk YE; van Bragt JJMH; Dankelman LLH; Dahlen SE; Brightling CE; Vijverberg SJH; Maitland-van der Zee AH
    Clin Exp Allergy; 2021 Aug; 51(8):992-1005. PubMed ID: 33887082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Managing severe asthma in adults: lessons from the ERS/ATS guidelines.
    Chung KF
    Curr Opin Pulm Med; 2015 Jan; 21(1):8-15. PubMed ID: 25405672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biologics in the treatment of asthma in children and adolescents.
    Bacharier LB; Jackson DJ
    J Allergy Clin Immunol; 2023 Mar; 151(3):581-589. PubMed ID: 36702649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How do biologicals and other novel therapies effect clinically used biomarkers in severe asthma?
    Upham JW; Jurak LM
    Clin Exp Allergy; 2020 Sep; 50(9):994-1006. PubMed ID: 32569412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.